SSRX Key Stats
- China Biotech In Review: Hisun-Pfizer, Merck-Simcere JVs Come Into Focus May 26
- 3SBio Inc. Announces Shareholders' Approval of the Amended Merger Agreement PR Newswire May 24
- China Biotech In Review: Chindex Buys Israeli Laser Company For $240 Million May 5
- 3SBIO INC. Financials May 4
- 3SBio Inc. Announces Extraordinary General Meeting of Shareholders PR Newswire May 2
- In Development-Stage Biotechs, Success Comes Down to One Asset: Expert Analyst B... May 1
- 3SBio Inc. Files Annual Report on Form 20-F for Fiscal Year 2012 PR Newswire May 1
- Asia Private Equity Weekly News, April 29, 2013 Reuters - UK Focus Apr 28
- China Biotech In Review: WuXi PharmaTech Contributes To Syros Pharma Funding Apr 28
- 3SBio Inc. Adjourns Extraordinary General Meeting of Shareholders PR Newswire Apr 25
SSRX Total Returns Comparison
This total returns chart shows the returns to an investor from both price appreciation and dividends (dividends are assumed to be reinvested). 3SBio is up 30.32% over the last year vs S&P 500 Total Return up 23.89%, Cell Therapeutics down 63.83%, and Antares Pharma up 16.15%.
Fundamental analysis of a business involves analyzing its financial statements and health, its management and competitive advantages. The key financial statements of a company are the income statement, balance sheet and cash flow statement.
Pro Ratings for SSRX
Pro Report PDF for SSRX
Download Pro Ratings, Key Stats, Performance Charts, Valuations, and Financials in an easy to print format.Download SSRX Pro Report PDF
Pro Strategies Featuring SSRX
Did 3SBio make it into our Pro Portfolio Strategies?
Start your YCharts Pro membership now to find out.